HKAM
ABBV icon

Horizon Kinetics Asset Management’s AbbVie ABBV Stock Holding History

Horizon Kinetics Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Sell
18,887
-322
-2% -$69.3K 0.05% 72
2026
Q1 		$4.18M Sell
19,209
-332
-2% -$73.6K 0.05% 76
2025
Q4 		$4.46M Sell
19,541
-812
-4% -$185K 0.06% 72
2025
Q3 		$4.71M Sell
20,353
-3,357
-14% -$684K 0.06% 68
2025
Q2 		$4.4M Sell
23,710
-447
-2% -$83.1K 0.05% 77
2025
Q1 		$5.06M Sell
24,157
-1,891
-7% -$368K 0.06% 69
2024
Q4 		$4.63M Buy
26,048
+203
+0.8% +$37.3K 0.06% 74
2024
Q3 		$5.1M Buy
25,845
+1,722
+7% +$321K 0.08% 69
2024
Q2 		$4.14M Buy
24,123
+106
+0.4% +$17.6K 0.07% 71
2024
Q1 		$4.37M Sell
24,017
-23
-0.1% -$3.96K 0.08% 69
2023
Q4 		$3.73M Sell
24,040
-784
-3% -$114K 0.08% 71
2023
Q3 		$3.7M Sell
24,824
-25
-0.1% -$3.67K 0.07% 70
2023
Q2 		$3.35M Sell
24,849
-254
-1% -$37.2K 0.07% 75
2023
Q1 		$4M Sell
25,103
-2,184
-8% -$334K 0.08% 69
2022
Q4 		$4.41M Hold
27,287
– – 0.07% 68
2022
Q3 		$3.66M Buy
27,287
+264
+1% +$37.9K 0.07% 67
2022
Q2 		$4.14M Sell
27,023
-1,345
-5% -$206K 0.09% 68
2022
Q1 		$4.6M Sell
28,368
-200
-0.7% -$29.1K 0.09% 74
2021
Q4 		$3.87M Hold
28,568
– – 0.09% 77
2021
Q3 		$3.08M Sell
28,568
-500
-2% -$57.1K 0.07% 91
2021
Q2 		$3.27M Buy
29,068
+61
+0.2% +$6.87K 0.07% 91
2021
Q1 		$3.14M Sell
29,007
-1,226
-4% -$131K 0.07% 85
2020
Q4 		$3.24M Sell
30,233
-2,639
-8% -$254K 0.11% 75
2020
Q3 		$2.88M Buy
32,872
+761
+2% +$71.6K 0.12% 84
2020
Q2 		$3.15M Sell
32,111
-1,040
-3% -$91.6K 0.11% 75
2020
Q1 		$2.53M Buy
33,151
+1,867
+6% +$159K 0.11% 76
2019
Q4 		$2.77M Buy
31,284
+192
+0.6% +$15.9K 0.08% 82
2019
Q3 		$2.35M Buy
31,092
+431
+1% +$29.5K 0.07% 99
2019
Q2 		$2.23M Buy
30,661
+508
+2% +$39.9K 0.06% 108
2019
Q1 		$2.43M Buy
+30,153
New +$2.47M 0.07% 103

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Horizon Kinetics Asset Management's ABBV Position: Q2 2026 in Review

Horizon Kinetics Asset Management reduced its AbbVie (ABBV) stake by 1.7% in Q2 2026, selling an estimated $69.3K and leaving 18,887 shares worth $4.75M. The position accounts for 0.05% of the portfolio, ranked #72.

Horizon Kinetics Asset Management first reported a position in ABBV in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.1M in Q3 2024. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Horizon Kinetics Asset Management held 18,887 shares of AbbVie worth $4.75M as of Q2 2026.
  • Horizon Kinetics Asset Management sold 322 AbbVie shares in Q2 2026, an estimated $69.3K.
  • AbbVie made up 0.05% of Horizon Kinetics Asset Management's portfolio in Q2 2026, its #72 holding.
  • Horizon Kinetics Asset Management first reported a position in AbbVie in Q1 2019 and has held it in 30 quarters since.
  • Horizon Kinetics Asset Management's AbbVie position peaked at $5.1M in Q3 2024.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.